
# Financial highlights

### Total Revenue<sup>1</sup>

Up 3% at actual rate of exchange to \$45,811 million (up 6% at CER), comprising Product Sales of \$43,789 million (up 2%; 4% at CER), Alliance Revenue of \$1,428 million (up 89%; 89% at CER) and Collaboration Revenue of \$594 million (down 1%; 1% at CER)

## Net cash flow from operating activities

Up 5% at actual rate of exchange to \$10,345 million



\$45.8bn

### \$10.345m \$9,808m \$5.963m

\$10.3bn

### Reported operating profit

Up 118% at actual rate of exchange to \$8,193 million (up 134% at CER)

2023					\$8,193m	
202	22					\$3,757m
	2021					\$1,056m

\$8.2bn

### Core operating profit

Up 9% at actual rate of exchange to \$14,534 million (up 14% at CER)

2023	\$14,534m	
2022		\$13,350m
2021		\$9,928m

\$14.5bn

### Reported EPS

Up 81% at actual rate of exchange to \$3.84 (up 96% at CER)

	2023	\$3.84	
	2022	\$2.12	
ĺ	2021	\$0.08	

\$3.84

### Core EPS

Up 9% at actual rate of exchange to \$7.26 (up 15% at CER)

2023	\$7.26		
2022		\$6.66	
2021		\$5.29	

\$7.26

### this Annual Report, all bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other. For more information:

// Denotes a scale break. Throughout

In relation to the inclusion of Reported performance, Core financial measures and constant exchange rate (CER) growth rates as used in this Annual Report, see the Financial Review from page 58.

For the reconciliation between Reported and Core performance, see the Reconciliation of Reported results to Core results in the Financial Review on page 62.

## Contents

### Strategic Report

Chief Executive Officer's Review 3

AstraZeneca at a Glance 5

What science can do: artificial intelligence 6

Healthcare in a Changing World 7

Our Purpose, Values and

Business Model 10

Our Strategy and

Key Performance Indicators 12

Therapy Area Review 16

- Oncology 16
- BioPharmaceuticals 20
  - Cardiovascular.
  - Renal & Metabolism 22
  - Respiratory & Immunology 24 Vaccines & Immune Therapies 26

Business Review 32

EU Taxonomy Disclosure 50

Task Force on Climate-related Financial Disclosures Summary Statement 51

Risk Overview 54

Financial Review 58

### Chair's Statement 2 Chair's Introduction 76

Corporate Governance Overview 77

Board of Directors 78

Corporate Governance

Senior Executive Team (SET) 80 Corporate Governance Report 81

Nomination and Governance

Committee Report 90

Science Committee Report 92

Sustainability Committee Report 93

Audit Committee Report 94

Directors' Remuneration Report 102 Remuneration Policy 127

### Financial Statements

Preparation of the Financial Statements and Directors Responsibilities 140

Directors' Annual Report on Internal

Controls over Financial Reporting 140 Auditors' Report 141

Consolidated Statements 148

Group Accounting Policies 152

Notes to the Group Financial

Group Subsidiaries and Holdings 211

Company Statements 216

Company Accounting Policies 218

Notes to the Company Financial Statements 220

Group Financial Record 223

### Additional Information

Shareholder information 225

Directors' Report 227

Sustainability supplementary information 230

Trade Marks 231

Glossary 232

Cautionary statement regarding forward-looking statements 236

<sup>&</sup>lt;sup>1</sup> As detailed from page 152, Total Revenue consists of Product Sales, Alliance Revenue and Collaboration Revenue.